Zuberitamab

Phase 3Monoclonal antibody

BBioRay Pharmaceutical Co., Ltd.

Zuberitamab is one of 143 small molecule programs targeting Mantle Cell Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mantle Cell LymphomaActive, not recruiting

Nephrotic SyndromeNot yet recruiting

EBV InfectionNot yet recruiting

TreatmentActive, not recruiting

Follicular LymphomaNot yet recruiting

Mantle Cell LymphomaPreclinical

Active, not recruiting

Nephrotic SyndromePhase 3

Not yet recruiting

EBV InfectionPhase 2

Not yet recruiting

TreatmentPhase 2

Active, not recruiting

Follicular LymphomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Zuberitamab

BBioRay Pharmaceutical Co., Ltd.

Phase 3

1 2

Biltricide

Bayer

Preclinical

4 3

Minipress

Pfizer

Preclinical

1 4

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 5

Theo-Dur

Pfizer

Preclinical

1 6

Alfenta

Jazz Pharmaceuticals

Preclinical

1 7

Niclocide

Bayer

Preclinical

1 8

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 9

Intuniv

PPromius Pharma, LLC

Preclinical

1 10

Clomid

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

EBV Infection

NCT07261215

Q2 2027

Phase 2Active, not recruiting

Membranous Nephropathy

NCT06642909

Q3 2028

N/ARecruiting

Mantle Cell Lymphoma

NCT07257510

Q4 2028

Phase 3Not yet recruiting

Nephrotic Syndrome

NCT07765914

Clinical

Trials by Indication[1]

Membranous Nephropathy1 trial

A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

Active, not recruiting·BBioRay Pharmaceutical Co., Ltd.·Phase 2·NCT06642909·135 enrolled

Treatment1 trial

Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL

Active, not recruiting·—·Phase 2·NCT07480863·65 enrolled

EBV Infection1 trial

Zuberitamab for EBV Infection Post-Allo-HSCT

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07261215·20 enrolled

Mantle Cell Lymphoma1 trial

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

Recruiting·PPeking University Third Hospital·N/A·NCT07257510·34 enrolled

Follicular Lymphoma1 trial

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06757894·50 enrolled

1 more indication

Nephrotic Syndrome1 trial

Efficacy and Safety of Single-dose Zuberitamab in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome: A Multicenter Randomized Controlled Trial

Not yet recruiting·CChildren's Hospital of Fudan University·Phase 3·NCT07765914·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Zuberitamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zuberitamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zuberitamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioRay Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: BBioRay Pharmaceutical Co., Ltd.

Zuberitamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2028

Q4 2028

Trials by Indication[1]

Membranous Nephropathy1 trial

Treatment1 trial

EBV Infection1 trial

Mantle Cell Lymphoma1 trial

Follicular Lymphoma1 trial

Nephrotic Syndrome1 trial

References

Drug Info

Quick Facts

Related News